Michael J. Mcbreen Sells 1,700 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock

Integra LifeSciences Holdings Co. (NASDAQ:IART) EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Integra LifeSciences Stock Up 0.2 %

Shares of NASDAQ IART traded up $0.05 during mid-day trading on Tuesday, hitting $24.63. The company had a trading volume of 347,199 shares, compared to its average volume of 1,083,627. The business’s 50-day simple moving average is $20.92 and its 200 day simple moving average is $23.94. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $45.42. The company has a market capitalization of $1.90 billion, a PE ratio of -271.19, a price-to-earnings-growth ratio of 0.84 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the firm earned $0.76 earnings per share. The business’s quarterly revenue was down .4% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Truist Financial lowered their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup upped their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Bank of America dropped their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Finally, Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday. They set an “underweight” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Cooke & Bieler LP raised its stake in shares of Integra LifeSciences by 12.4% during the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after buying an additional 388,710 shares in the last quarter. Sachem Head Capital Management LP purchased a new position in Integra LifeSciences in the third quarter worth $44,153,000. Dimensional Fund Advisors LP lifted its holdings in Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after acquiring an additional 12,766 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Integra LifeSciences by 15.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after purchasing an additional 125,620 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Integra LifeSciences by 64.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after purchasing an additional 335,557 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.